Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases.

Abstract

The delivery of cures for retinal diseases remains problematic. There are four main challenges: passing through multiple barriers of the eye, the delivery to particular retinal cell types, the capability to carry different forms of therapeutic cargo and long-term therapeutic efficacy. Lipid-based nanoparticles (LBNPs) are potent to overcome these challenges due to their unique merits: amphiphilic nanoarchitectures to pass biological barriers, vary modifications with specific affinity to target cell types, flexible capacity for large and mixed types of cargos and slow-release formulations for long-term treatment. We have reviewed the latest research on the applications of LBNPs for treating retinal diseases and categorized them by different payloads. Furthermore, we identified technical barriers and discussed possible future development for LBNPs to expand the therapeutic potential in treating retinal diseases.

• Authors: Shaoxue Zeng, Yingying Chen, Fanfan Zhou, Ting Zhang, Xiaohui Fan, Wojciech Chrzanowski, Mark C Gillies, Ling Zhu
• Journal: Advanced drug delivery reviews (Adv Drug Deliv Rev) Vol. 199 Pg. 114965 (08 2023) ISSN: 1872-8294 [Electronic] Netherlands
• PMID: 37315899 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023. Published by Elsevier B.V.

Chemical References

• Drug Carriers
• Lipids
• Liposomes

Topics

• Humans
• Drug Carriers (therapeutic use)
• Lipids (therapeutic use)
• Liposomes
• Retinal Diseases (drug therapy)
• Drug Delivery Systems
• Nanoparticles